On group extensions

Thesis (M.A.)--Boston University Bibliography

Control-based Scheduling in a Distributed Stream Processing System

Stream processing systems receive continuous streams of messages with raw information and produce streams of messages with processed information. The utility of a stream-processing system depends, in part, on the accuracy and timeliness of the output. Streams in complex event processing systems are processed on distributed systems; several steps are taken on different processors to process each incoming message, and messages may be enqueued between steps. This paper deals with the problems of distributed dynamic control of streams to optimize the total utility provided by the system. A challenge of distributed control is that timeliness of output depends only on the total end-toend time and is otherwise independent of the delays at each separate processor whereas the controller for each processor takes action to control only the steps on that processor and cannot directly control the entire network. This paper identifies key problems in distributed control and analyzes two scheduling algorithms that help in an initial analysis of a difficult problem

Reliable Synchronization Primitives for Java

Java is an architecture-independent, object-oriented language designed to facilitate code-sharing across the Internet in general, via the Web in particular. Java is multithreaded, providing thread creation and synchronization constructs based on generalized monitors. Although these primitives are appropriate for many windowing applications, they are not necessarily well-suited for the larger class of multithreaded programs that occur as part of distributed systems. We demonstrate how the Java primitives, in conjunction with the object-oriented aspects of the language, can be used to implement a collection of other traditional synchronization paradigms. These paradigms are formally specified, their implementations are rigorously verified, and their use is illustrated with several examples

HYALURONAN-A NOVEL POLYMER ISOLATED FROM MUTATED CLINICAL BACTERIAL ISOLATE

Objective: This study was done to optimize the production parameters involved in the isolation of hyaluronan (HA) from UV mutated a clinical strain of Klebsiella pneumonia (M 3020).Methods: Glucose and nitrogen enriched media (D-glucose, L-glutamic acid, and peptone) were utilized to cultivate the clinical isolate K. pneumoniae. The strain was Ultra Violet (UV) radiation mutated (254 nm, 25 min) and HA production was optimized by parameters such as pH and temperature. The isolated HA from the fermented broth was subjected to purification by isopropyl alcohol and silica gel and further dried by lyophilization. Produced HA was confirmed with UV and Fourier Transform Infra-Red (FT-IR) spectroscopy.Results: UV treated strain at 254 nm for 25 min predominantly produce a high quantity of HA (3.5 g/l) in 37 °C, 300 rpm and pH 6.8 at 24 h run. UV and IR spectrum of produced HA showed strong similarity with the standard hyaluronan.Conclusion: To conclude, high quantity and quality of HA can be isolated from mutated clinical strains of K. pneumoniae

Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation

Busulfan pharmacokinetic parameters are useful in predicting the outcome of allogeneic bone marrow transplantation (BMT). Standard pharmacokinetic measurements require multiple blood samples. Various limited sampling models (LSM) have been proposed for reducing the sample number required for these measurements, essentially for patients with malignant disorders undergoing BMT. This study was undertaken to evaluate the existing LSM for busulfan pharmacokinetics to find out the most suitable method for patients with thalassaemia major undergoing BMT. Busulfan levels in plasma samples were analysed by HPLC. The AUC calculated by non-compartmental analysis using the program 'TOPFIT' was compared with previously published LSMs. Our seven sample pharmacokinetic data for AUC calculation was compared with the published LSMs. The three sample models suggested by Chattergoon et al and Schuler et al showed significant agreement with AUC TOPFIT (R2 = 0.98 and 0.94, respectively) in our clinical context. Other models resulted in significant over or under representation of observed values (Vassal's model R2 = 0.61; Chattergoon's two sample model R2 = 0.84; four sample model R2 = 0.83; Schuler's two sample model R2 = 0.79). By these data the three sample LSM proposed by Chattergoon et al and Schuler et al are suitable for calculation of the AUC in patients with thalassaemia major undergoing BMT conditioned with oral busulfan

A STUDY ON DIFFERENT PELLET FORMATION TECHNIQUES AND ITS EVALUATION PARAMETERS-A REVIEW

This review article deals with the various pelletization techniques utilized in the pharmaceutical industry for spheroidal particle production i.e., pellet for mainly oral administration which can be further formulated into several other dosage forms such as tablets, capsules or can be administered as such. Now-a-days oral administration has become the most versatile, convenient and common route of drug administration which ultimately focuses on patient compliance. The technique which is setting horizon in pelletization is “Extrusion Spheronization” because of its simple and easy steps involved in pellet production in a faster way. This review also includes the characterization and evaluation of pellets to ensure its quality, safety and efficacy to give out the required therapeutic activity after administration

A multichannel feature-based approach for longitudinal lung CT registration in the presence of radiation induced lung damage

Quantifying parenchymal tissue changes in the lungs is imperative in furthering the study of radiation-induced lung damage (RILD). Registering lung images from different time-points is a key step of this process. Traditional intensity-based registration approaches fail this task due to the considerable anatomical changes that occur between timepoints. This work proposes a novel method to successfully register longitudinal pre- and post-radiotherapy (RT) lung CT scans that exhibit large changes due to RILD, by extracting consistent anatomical features from CT (lung boundaries, main airways, vessels) and using these features to optimise the registrations. Pre-RT and 12-month post-RT CT pairs from fifteen lung cancer patients were used for this study, all with varying degrees of RILD, ranging from mild parenchymal change to extensive consolidation and collapse. For each CT, signed distance transforms from segmentations of the lungs and main airways were generated, and the Frangi vesselness map was calculated. These were concatenated into multi-channel images and diffeomorphic multichannel registration was performed for each image pair using NiftyReg. Traditional intensity-based registrations were also performed for comparison purposes. For the evaluation, the pre- and post-registration landmark distance was calculated for all patients, using an average of 44 manually identified landmark pairs per patient. The mean (standard deviation) distance for all datasets decreased from 15.95 (8.09) mm pre-registration to 4.56 (5.70) mm post-registration, compared to 7.90 (8.97) mm for the intensity-based registrations. Qualitative improvements in image alignment were observed for all patient datasets. For four representative subjects, registrations were performed for 3 additional follow-up timepoints up to 48-months post-RT and similar accuracy was achieved. We have demonstrated that our novel multichannel registration method can successfully align longitudinal scans from RILD patients in the presence of large anatomical changes such as consolidation and atelectasis, outperforming the traditional registration approach both quantitatively and through thorough visual inspection

Neurodevelopment: The Impact of Nutrition and Inflammation During Early to Middle Childhood in Low-Resource Settings

The early to middle childhood years are a critical period for child neurodevelopment. Nutritional deficiencies, infection, and inflammation are major contributors to impaired child neurodevelopment in these years, particularly in low-resource settings. This review identifies global research priorities relating to nutrition, infection, and inflammation in early to middle childhood neurodevelopment. The research priority areas identified include: (1) assessment of how nutrition, infection, or inflammation in the preconception, prenatal, and infancy periods (or interventions in these periods) affect function in early to middle childhood; (2) assessment of whether effects of nutritional interventions vary by poverty or inflammation; (3) determination of the feasibility of preschool- and school-based integrated nutritional interventions; (4) improved assessment of the epidemiology of infection- and inflammation-related neurodevelopmental impairment (NDI); (5) identification of mechanisms through which infection causes NDI; (6) identification of noninfectious causes of inflammation-related NDI and interventions for causes already identified (eg, environmental factors); and (7) studies on the effects of interactions between nutritional, infectious, and inflammatory factors on neurodevelopment in early to middle childhood. Areas of emerging importance that require additional study include the effects of maternal Zika virus infection, childhood environmental enteropathy, and alterations in the child’s microbiome on neurodevelopment in early to middle childhood. Research in these key areas will be critical to the development of interventions to optimize the neurodevelopmental potential of children worldwide in the early to middle childhood years

Salvage with a mini-allograft after primary engraftment failure following autologous transplant for multiple myeloma

This article does not have an abstract

Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia

Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown. In vitro studies suggest hydroxyurea could increase malaria severity, and hydroxyurea-associated neutropenia could worsen infections. NOHARM (Novel use Of Hydroxyurea in an African Region with Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Uganda, comparing hydroxyurea to placebo at 20 ± 2.5 mg/kg per day for 12 months. The primary outcome was incidence of clinical malaria. Secondary outcomes included SCA-related adverse events (AEs), clinical and laboratory effects, and hematological toxicities. Children received either hydroxyurea (N = 104) or placebo (N = 103). Malaria incidence did not differ between children on hydroxyurea (0.05 episodes per child per year; 95% confidence interval [0.02, 0.13]) vs placebo (0.07 episodes per child per year [0.03, 0.16]); the hydroxyurea/placebo malaria incidence rate ratio was 0.7 ([0.2, 2.7]; P = .61). Time to infection also did not differ significantly between treatment arms. A composite SCA-related clinical outcome (vaso-occlusive painful crisis, dactylitis, acute chest syndrome, splenic sequestration, or blood transfusion) was less frequent with hydroxyurea (45%) than placebo (69%; P = .001). Children receiving hydroxyurea had significantly increased hemoglobin concentration and fetal hemoglobin, with decreased leukocytes and reticulocytes. Serious AEs, sepsis episodes, and dose-limiting toxicities were similar between treatment arms. Three deaths occurred (2 hydroxyurea, 1 placebo, and none from malaria). Hydroxyurea treatment appears safe for children with SCA living in malaria-endemic sub-Saharan Africa, without increased severe malaria, infections, or AEs. Hydroxyurea provides SCA-related laboratory and clinical efficacy, but optimal dosing and monitoring regimens for Africa remain undefined. This trial was registered at www.clinicaltrials.gov as #NCT01976416